PL3957320T3 - Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego - Google Patents

Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Info

Publication number
PL3957320T3
PL3957320T3 PL21174249.9T PL21174249T PL3957320T3 PL 3957320 T3 PL3957320 T3 PL 3957320T3 PL 21174249 T PL21174249 T PL 21174249T PL 3957320 T3 PL3957320 T3 PL 3957320T3
Authority
PL
Poland
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
PL21174249.9T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL3957320T3 publication Critical patent/PL3957320T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL21174249.9T 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego PL3957320T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08

Publications (1)

Publication Number Publication Date
PL3957320T3 true PL3957320T3 (pl) 2024-02-19

Family

ID=60186557

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Country Status (16)

Country Link
EP (3) EP3397273B1 (pl)
CN (1) CN108472340A (pl)
CY (1) CY1124637T1 (pl)
DK (2) DK3397273T3 (pl)
ES (2) ES2965190T3 (pl)
FI (1) FI3957320T3 (pl)
HK (1) HK1253014A1 (pl)
HR (2) HRP20210894T1 (pl)
HU (2) HUE064049T2 (pl)
LT (2) LT3957320T (pl)
PL (2) PL3397273T3 (pl)
PT (2) PT3397273T (pl)
RS (2) RS64843B1 (pl)
SI (2) SI3957320T1 (pl)
SM (2) SMT202300412T1 (pl)
TW (3) TW202506173A (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP2444102B1 (en) 2003-01-31 2015-04-08 The Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
DK3470077T3 (da) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
ES2585584T3 (es) * 2009-05-26 2016-10-06 Amicus Therapeutics, Inc. Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida
PT2844279T (pt) 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
KR20250004926A (ko) * 2014-09-30 2025-01-08 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제

Also Published As

Publication number Publication date
EP3397273A1 (en) 2018-11-07
CY1124637T1 (el) 2022-07-22
TWI849380B (zh) 2024-07-21
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
DK3957320T5 (da) 2024-08-05
HUE054733T2 (hu) 2021-09-28
CN108472340A (zh) 2018-08-31
LT3397273T (lt) 2021-06-25
HRP20210894T1 (hr) 2021-07-23
TWI753874B (zh) 2022-02-01
ES2883844T3 (es) 2021-12-09
RS64843B1 (sr) 2023-12-29
TW202506173A (zh) 2025-02-16
EP3957320B1 (en) 2023-08-23
DK3957320T3 (da) 2023-11-27
EP4285902B1 (en) 2025-11-19
TW202245831A (zh) 2022-12-01
EP3397273B1 (en) 2021-05-19
EP4285902A2 (en) 2023-12-06
SI3397273T1 (sl) 2021-11-30
PT3397273T (pt) 2021-08-09
LT3957320T (lt) 2023-12-11
TW201726163A (zh) 2017-08-01
EP3957320A1 (en) 2022-02-23
PL3397273T3 (pl) 2021-12-06
FI3957320T3 (fi) 2023-11-23
SMT202100452T1 (it) 2021-09-14
ES2965190T3 (es) 2024-04-11
DK3397273T3 (da) 2021-08-09
HUE064049T2 (hu) 2024-02-28
HK1253014A1 (zh) 2019-06-06
SMT202300412T1 (it) 2024-01-10
SI3957320T1 (sl) 2024-01-31
HRP20231465T1 (hr) 2024-03-01
EP4285902A3 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
IL259876B (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
ZA201907552B (en) Recombinant human acid alpha-glucosidase
IL255506A (en) A method for treating a neurological disease
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EP3137063A4 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine
EP3310377A4 (en) Method of treating crohn's disease
IL253726A0 (en) Preparations for the treatment of inflammatory diseases related to uric acid
GB201515244D0 (en) Treatment of inflammatory disease or condition
PT3340975T (pt) Formulação para o tratamento de acne
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
SI3957320T1 (sl) Dopolnjena kisla alfa glukozidaza za zdravljenje Pompejeve bolezni
HK40067011A (zh) 用於治疗神经系统疾病的方法
PL3307292T3 (pl) Formulacje do leczenia zmian na błonach śluzowych
GB201504413D0 (en) Treatment of disease
GB201621398D0 (en) Treatment of emt-associated disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
HK1259743A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
AU2015902358A0 (en) Treatment of inflammatory disease
HK1230506A1 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine